Gemcitabine confirmed as the first-line therapy for pancreatic cancer

被引：3
|
作者：
Claire Greenhill
机构：
来源：
Nature Reviews Gastroenterology & Hepatology | 2011年 / 8卷 / 1期
关键词：
D O I：
10.1038/nrgastro.2010.200
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3 / 3
相关论文
共 50 条
  • [1] Clinical benefit with gemcitabine (GEM) as first-line therapy for patients with advanced pancreatic cancer (APC)
    Manzano, H
    Esquerdo, G
    Rifa, J
    Aguiar, D
    Arrivi, A
    Pazo, R
    Martin, J
    Terrasa, J
    ANNALS OF ONCOLOGY, 1998, 9 : 54 - 54
  • [2] A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
    Steven J. Cohen
    Mark M. Zalupski
    Manuel R. Modiano
    Paul Conkling
    Yehuda Z. Patt
    Peg Davis
    Robert T. Dorr
    Michelle L. Boytim
    Evan M. Hersh
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 287 - 294
  • [3] Gemcitabine Plus Irinotecan as First-Line Weekly Therapy in Locally Advanced and/or Metastatic Pancreatic Cancer
    Neri, B.
    Cipriani, G.
    Grifoni, R.
    Molinara, E.
    Pantaleo, P.
    Rangan, S.
    Vannini, A.
    Tonelli, P.
    Valeri, A.
    Pantalone, D.
    Taddei, A.
    Bechi, P.
    ONCOLOGY RESEARCH, 2009, 17 (11-12) : 559 - 564
  • [4] A phase I study of imexon plus gemcitabine as first-line therapy for advanced pancreatic cancer
    Cohen, Steven J.
    Zalupski, Mark M.
    Modiano, Manuel R.
    Conkling, Paul
    Patt, Yehuda Z.
    Davis, Peg
    Dorr, Robert T.
    Boytim, Michelle L.
    Hersh, Evan M.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (02) : 287 - 294
  • [5] Erlotinib/gemcitabine improves survival in first-line pancreatic cancer patients
    不详
    ONCOLOGY-NEW YORK, 2004, 18 (11): : 1383 - 1383
  • [6] EFFICACY AND SAFETY OF GEMCITABINE AS FIRST-LINE THERAPY IN PATIENTS AGED 65 AND OLDER WITH ADVANCED PANCREATIC CANCER
    Kito, Yosuke
    Todaka, Akiko
    Fukutomi, Akira
    Kunieda, Kenji
    Tsushima, Takahiro
    Yokota, Tomoya
    Machida, Nozomu
    Yamazaki, Kentaro
    Onozawa, Yusuke
    Yasui, Hirofumi
    ANNALS OF ONCOLOGY, 2014, 25
  • [7] Details of response with first-line gemcitabine and nab-paclitaxel therapy in patients with advanced pancreatic cancer
    Nagata, Y.
    Kinoshita, C.
    Ishimoto, U.
    Kano, T.
    Ishikawa, M.
    Mikuni, H.
    Nakatsuka, K.
    Harada, K.
    Nishimura, T.
    Noguchi, M.
    Sawada, R.
    Amano, K.
    Saruta, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [8] First-line therapy for advanced pancreatic cancer with gemcitabine and docetaxel versus gemcitabine and erlotinib: A multivariate matched pair analysis.
    Stuebs, P.
    Habermann, P.
    Zierau, K.
    Schuette, K.
    Fahlke, J.
    Ridwelski, K.
    Kettner, E.
    Lippert, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [9] Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
    Davide Melisi
    Rocio Garcia-Carbonero
    Teresa Macarulla
    Denis Pezet
    Gael Deplanque
    Martin Fuchs
    Jorg Trojan
    Helmut Oettle
    Mark Kozloff
    Ann Cleverly
    Claire Smith
    Shawn T. Estrem
    Ivelina Gueorguieva
    Michael M. F. Lahn
    Al Blunt
    Karim A. Benhadji
    Josep Tabernero
    British Journal of Cancer, 2018, 119 : 1208 - 1214
  • [10] Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer
    Melisi, Davide
    Garcia-Carbonero, Rocio
    Macarulla, Teresa
    Pezet, Denis
    Deplanque, Gael
    Fuchs, Martin
    Trojan, Jorg
    Oettle, Helmut
    Kozloff, Mark
    Cleverly, Ann
    Smith, Claire
    Estrem, Shawn T.
    Gueorguieva, Ivelina
    Lahn, Michael M. F.
    Blunt, Al
    Benhadji, Karim A.
    Tabernero, Josep
    BRITISH JOURNAL OF CANCER, 2018, 119 (10) : 1208 - 1214
12345